Background: The p73 gene is a p53 homologue that induces apoptosis and inhibits cell proliferation. Nterminal truncated isoforms of p73 (DNp73) act as dominant-negative inhibitors of wild-type p53 and TAp73 and result in tumour growth in nude mice. Aims: To detect DNp73 expression in 24 benign prostatic hyperplasia samples, 33 prostate carcinomas, and five normal samples and to evaluate the relation between DNp73, TAp73 concentrations, and the clinicopathological characteristics of patients with prostate cancer. Methods: TAp73 was determined by real time polymerase chain reaction (PCR); DNp73 and DN'p73 were assessed using reverse transcription PCR. western blotting was used to analyse protein expression. p53 mutation was determined by immunohistochemistry. Results: A significant increase of DNp73 was seen in 20 of 33 carcinomas and 17 of 24 benign prostate hyperplasia tissues, but in none of the normal samples. None of the specimens expressed DN'p73. No significant relation was found between TAp73 expression and clinical parameters. The incidence of positive expression of DNp73 correlated with the Gleason score in prostate carcinomas. Cancer samples with wild-type p53 had significantly higher expression of DNp73 than p53 mutant cancers. Conclusion: These data suggest a potential role for DNp73 in prostate cancer progression.
P rostate cancer (PCa) is the most commonly diagnosed malignancy in the male population of the Western world and the incidence of PCa is rising rapidly in China. 1 The molecular basis of PCa is still poorly understood. Moreover, the molecular mechanisms at the basis of the favourable outcome in patients with disseminated disease are not yet known, and understanding these mechanisms might have important implications.
The tumour suppressor gene p53 is the most commonly mutated gene in human cancer. The p53 gene encodes the p53 protein, which is a key regulator of the cell cycle, controlling the transition from G1 phase to S phase. Although alterations in the p53 gene are found in more than half of all human cancers, the role of p53 mutations in human prostate cancer is controversial. According to most studies, mutations in the p53 gene are rare in early, localised prostate cancer, whereas they are found in about 20-40% of advanced (metastatic and/or hormone refractory) prostate carcinomas. 2 3 ''p73 encodes a variety of protein isoforms through the use of alternative promoters at the 59-end or differential splicing at the 39-end'' p73 was recently identified as structurally and functionally homologous to tumour suppressor protein p53 from its sequence homology and gene organisation: a transactivation domain, a DNA binding domain, and an oligomerisation domain. 4 As such, p73 can exert p53-like activities in various contexts, including transactivating p53 target genes, such as p21, MDM2, or BAX, leading to apoptosis and cell growth arrest. 5 In contrast to the p53 gene, which encodes one major protein, p73 encodes a variety of protein isoforms through the use of alternative promoters at the 59-end or differential splicing at the 39-end. 6 At the 59-end, four different Nterminally truncated isoforms (DNp73, DN'p73, Ex2p73, and Ex2/3p73) have now been found in human cancers and/or cancer cells. Each of these isoforms lack all or most of the transactivation domain and therefore are collectively called DTAp73. DTAp73 products are generated either via alternative exon splicing of the P1 promoter transcript (to produce DN'p73, Ex2p73, and Ex2/3p73) or via alternative use of the P2 promoter in intron 3 (to produce DNp73). 7 8 Of importance, the transcripts DNp73 and DN'p73 encode the same protein product. DNp73 acts as a potent transdominant inhibitor of wild-type p53 and the transactivation competent TAp73 and confers drug resistance to the wild-type p53 harbouring tumour cells. 9 This is the first report on an association between expression of DNp73 (DN'p73) and TAp73 in patients with prostate carcinoma and benign prostate hyperplasia (BPH). Our study was designed to detect DNp73 using reverse transcription polymerase chain reaction (RT-PCR) and western blot analysis to evaluate the relation between DNp73 expression and the biological parameters of the patients.
MATERIAL AND METHODS

Cell culture
LNCaP, DU145, SP3031, 22Rv1, PC-3, and K-562 cells were obtained from the American Type Culture Collection (Rockville, Maryland, USA). They were cultured in RPMI 1640 (HyClone, Logan, Utah, USA) containing 10% fetal bovine serum, 100 units/ml penicillin, and 100 mg/ml streptomycin in a 5% CO 2 atmosphere at 37˚C. Real time PCR and RT-PCR Total RNA was extracted from cells and tissues using the RNAeasy minikit (Qiagen, Hilden, Germany). Total RNA (2 mg) was reverse transcribed using Superscript II RT (Invitrogen, Carlsbad, California, USA) according to the manufacturer's protocol. Real time PCR was performed using the ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City, California, USA) with SYBR green for determination of TAp73 mRNA. Reactions were performed in a total volume of 20 ml, including 10 ml 26 SYBR Green PCR master mix (Applied Biosystems), 5 ml of each primer at a 5 mM concentration, and 1 ml of the previously reverse transcribed cDNA template. The cycling conditions were as follows: 10 minutes at 95˚C, and 40 cycles of 15 seconds at 95˚C followed by one minute at 60˚C.
Patients and tissues
Calculations were performed using values of average cycle threshold (Ct) as the calibrator from normal samples. For each experimental sample, the Ct of the target, normalised to an endogenous reference and relative to the calibrator, is given by: 2 2DDCt . Routine RT-PCR for detection of DNp73 and DN'p73 was carried out using HotStarTaq DNA polymerase (Qiagen). 
Immunohistochemical detection of mutant p53
Tissue sections (5 mm thick) of fixed, paraffin wax embedded specimens were cut, mounted on poly-L-lysine slides (Superfrost Plus; VWR, Milan, Italy), and then dewaxed in Histoclear. Specimens were rehydrated by sequential washing in ethanol solutions. The sections were then immersed in 0.3% hydrogen peroxide in methanol for 20 minutes at room temperature to block endogenous peroxidase activity. After non-specific sites had been blocked with 5% normal goat serum in phosphate buffered saline (PBS) for one hour, the sections were incubated with anti-p53 (pAb240; Chemicon, Temecula, California, USA) monoclonal antibody overnight at 4˚C. In subsequent steps, we used a Vectastain ABC kit (Vector, Burlingame, California, USA) and DAB (diaminobenzidine) as a chromogen. The sections were then counterstained with haematoxylin. In each immunohistochemical staining, we performed additional staining without primary antibody in parallel as a negative control. Expression was classified as negative if , 5% of tumour cells were positive and as positive if . 5% were positive. Positive p53 immunostaining has been reported to be related to p53 mutations that increase the half life of the p53 protein, leading to intracellular accumulation. 10 11 Therefore, from now on we will refer to immunodetectable p53 as mutant p53.
Western blot analysis
Specimens were homogenised in Triton X-100 buffer with 500mM HEPES (pH.7.0), 150mM NaCl, 10% glycerol, 1mM EDTA, and 1.2% Triton X-100. The homogenate was centrifuged at 1000 6g for 15 minutes to remove whole cells, nuclei, and mitochondria. The supernatant was used to measure the protein concentration. An equal amount of protein (30 mg) was loaded on to 10% polyacrylamide gels, followed by transfer to a nitrocellulose membrane sheet. The membranes were blocked with 5% skimmed milk in 0.01M PBS, pH 7.4. After incubation with primary antibodies, membranes were washed with PBS for 10 minutes three times and then incubated with horseradish peroxidase conjugated second antibody. Signals were detected with an ECL system (Amersham Pharmacia Biotech, St Louis, Missouri, USA).
The following antibodies were used for western blot: a monoclonal antibody against p73 (Ab-1; Calbiochem, Cambridge, Massachusetts, USA), a polyclonal antibody against DNp73 (sc-23429; Santa Cruz Biotechnology, Santa Cruz, California, USA), and a monoclonal anti-GAPDH antibody (Chemicon)
Statistical analysis
The association between DNp73 expression, TAp73, expression, and other prognostic factors and the differences in the distribution of the groups of patients were assessed by the x 2 test or Fisher's exact test. All analyses ware two tailed and were considered significant when p , 0.05.
RESULTS
Expression of TAp73
A change of threefold or greater was considered significant for TAp73 expression. The degree of expression was determined as the ratio between the TAp73 gene tested and the reference GAPDH gene to correct for variations in the amounts of RNA. Ratios were then normalised such that the mean ratio of the five normal prostate samples equalled 1.00. Overexpression of TAp73 was seen in 24 of 33 primary carcinomas, in three of five carcinoma cell lines (LNCaP, SP3031, and 22Rv1), and in 19 of 24 BPH specimens. The mean ratio of the TAp73 of the PCa and BPH samples was 9.65 and 11.21 times the mean ratio of the normals, respectively (p , 0.01) (fig 1) .
Expression of DNp73
The normal tissues did not express detectable amounts of DNp73 transcripts, as determined by RT-PCR. Most of the tumours and BPH specimens showed increased expression of DNp73 (fig 2) . A significant increase in DNp73 was seen in 20 of 33 tumours, 17 of 24 BPH samples, and two of five carcinoma cell lines (LNCaP and 22 Rv1). We were unable to detect DN'p73 in the samples. Nucleic acid sequencing revealed that the positive band represents the N-terminal truncated isoform DNp73. We failed to reveal a relation between TAp73 and DNp73 mRNA expression in PCa and BPH samples (tables 2, 3). Table 4 summarises the various clinicopathological characteristics of the patients with cancer in relation to DNp73 and TAp73 mRNA expression. Positive DNp73 expression correlated with tumour Gleason score (p = 0.037). There was no significant relation between DNp73 expression and age at surgery, TNM stage, or PSA serum concentration. There was also no association between TAp73 expression and these clinical parameters.
Western blotting
To verify whether our RT-PCR results reflected p73 protein expression, selected samples were analysed by western blotting using an antibody that recognises an epitope in the N-terminal transactivation domain of p73 and an antibody against DNp73, which recognises DNp73 only, with no crossreactivity with TAp73 isoforms. Both TAp73 and DNp73 expression were found in the tumour and BHP tissues, but not in normal tissues. As shown in fig 3, protein concentrations correlated with the RT-PCR data.
Immunohistochemistry
We determined the p53 mutation status in our tumour collection via immunohistochemistry. Ten of 33 tumours and one of 24 BPH specimens expressed mutant p53 (fig 4) . Significantly higher expression of the DNp73 isoform was found in p53 wild-type tumours, compared with p53 mutant tumours (p = 0.026). In contrast, there was no difference in the prevalence of TAp73 upregulation between wild-type and mutant tumours (table 5) .
DISCUSSION
We analysed the expression of two N-terminally truncated p73 isoforms in 33 prostate carcinomas and 24 BPHs of all histological types, and correlated the results with clinicopathological parameters. The most striking finding was the high prevalence of upregulation of DNp73 in prostate specimens (20 of 33 PCa and 17 of 24 BPH specimens), suggesting that deregulation of DNp73 is a crucial event in the pathogenesis of this tumour. DNp73 is derived from the P2 promoter. In contrast, none of the specimens showed upregulation of the P1 promoter derived DN'p73 transcript. We conclude that DNp73, rather than DN'p73, is the main contributor to total DNp73 upregulation in prostate cancers. Increased expression of wild-type p73 in tumour samples compared with normal tissues has been reported frequently, [12] [13] [14] [15] and in some cases overexpression of p73 correlated with an advanced tumour stage or poor prognostic parameters. 16 17 Consistent with our findings, increased TAp73 expression has been reported previously in prostate tumours compared with normal tissue. 18 As shown as table 4, no significant differences were detected concerning median age, TNM stage, Gleason score, or PSA serum concentration, indicating that TAp73 expression cannot be considered as a prognostic marker. However, DNp73 expression was strongly associated with the Gleason score, suggesting a potential role of DNp73 transcripts in prostate carcinoma progression, because the Gleason score is considered one of the most important prognostic indicators for prostate cancer. Our results are also in agreement with two recent DNp73 studies, 19 20 which both found significantly higher expression of DNp73 in advanced tumours. Interestingly, we found that the P2 promoter derived DNp73 transcript was more abundant in benign prostate hyperplasia (17 of 24) than in PCa (20 of 33). In line with our observations, previous results showed that DNp73, the predominant isoform in benign naevi, was not upregulated significantly in melanoma tissue. 21 This might be because the P2 promoter has a lower sensitivity for E2F1, as indicated by a previous study on Saos-2 cells, 22 where there was a strong induction of P1 promoter derived transcripts after conditional activation of E2F1, whereas the P2 promoter regulated DNp73 transcript showed only a modest induction by E2F1. Another possible reason is that DNp73 expression is epigenetically regulated in prostate tissues. It was reported previously that methylation of the DNp73 59-region in neuroblastoma was associated with the absence of expression. 23 We speculate that differences in methylation of DNp73 contributes to this discrepancy. It is currently unclear why the P1 promoter derived DN'p73 transcript is hardly expressed in prostate neoplastic cells. One possible explanation might be that different splice factors are required for the generation of aberrantly spliced transcripts from the P1 promoter. Another surprising result of our study is the strong correlation between p53 status and the upregulation of dominant-negative DNp73 in tumours. Considering the fact that oncogene induced upregulation of p73 expression causes apoptosis, sustained overexpression of p73 therefore requires inhibition of its inherent proapoptotic activity. 24 This could be achieved by p53 mutants, which inhibit the putative tumour suppressor action of p73 in a dominant-negative fashion by generating defective hetero-oligomers with wild-type p73. However, reduction of the apoptotic potential of p73 by mutant p53 cannot account for all cases of p73 overexpression. In our study, no correlation between p53 mutations and p73 overexpression could be detected in prostate carcinoma. In this respect, the interaction between p53 and DNp73 might contribute to malignancy in the absence of physical damage to the p53 gene. p53 is capable of inducing DNp73, a protein that can block p53 action by competing for p53 DNA binding sites. p53 induces DNp73 by directly binding to its promoter.
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DNp73 counteracts p53 action on its own promoter, creating an additional feedback loop that finely tunes the entire system. In addition, a similar loop regulates TAp73 action, because DNp73 expression is also induced by TAp73, and DNp73 also regulates the function of the TA forms. This suggests that DNp73 plays an important role in regulating p53 function and that its overexpression could play a role in tumorigenesis by generating a functional block of p53. We reasoned that if DNp73 isoforms are indeed oncogenic inhibitors of p53 and TAp73 in vivo, their upregulation should occur preferentially in wild-type p53 tumours, and our results support this notion.
In conclusion, our study identified a novel biological feature of PCa and BPH. Additional laboratory studies are needed to elucidate the genetic mechanism underlying the frequent expression of DNp73 in PCa and BPH and its biological consequences on cell survival.
